Familial Prostate Cancer
Primary Purpose
Neoplastic Syndromes, Hereditary, Prostatic Neoplasms
Status
Completed
Phase
Locations
United States
Study Type
Observational
Intervention
Sponsored by
About this trial
This is an observational trial for Neoplastic Syndromes, Hereditary focused on measuring Familial, Inherited Prostate Cancer, Linkage, Prostate Cancer
Eligibility Criteria
Families will be identified with two or more first degree relatives affected with prostate cancer or with one male with prostate cancer that developed before age 55. Must have clinical evidence of prostate cancer in the family.
Sites / Locations
- National Cancer Institute (NCI)
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00001377
First Posted
November 3, 1999
Last Updated
March 3, 2008
Sponsor
National Cancer Institute (NCI)
1. Study Identification
Unique Protocol Identification Number
NCT00001377
Brief Title
Familial Prostate Cancer
Official Title
Familial Prostate Cancer
Study Type
Observational
2. Study Status
Record Verification Date
December 1999
Overall Recruitment Status
Completed
Study Start Date
December 1993 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2000 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Cancer Institute (NCI)
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to identify affected individuals in families with prostate cancer and to use this information to identify genetic markers closely-linked to the disease gene.
Detailed Description
The purpose of this study is to identify affected individuals in families with prostate cancer and to use this information to identify genetic markers closely-linked to the disease gene.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neoplastic Syndromes, Hereditary, Prostatic Neoplasms
Keywords
Familial, Inherited Prostate Cancer, Linkage, Prostate Cancer
7. Study Design
Enrollment
200 (false)
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Families will be identified with two or more first degree relatives affected with prostate cancer or with one male with prostate cancer that developed before age 55.
Must have clinical evidence of prostate cancer in the family.
Facility Information:
Facility Name
National Cancer Institute (NCI)
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
8625320
Citation
Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res. 1996 May 15;56(10):2411-6.
Results Reference
background
PubMed Identifier
9041206
Citation
Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linehan WM, Topalian SL. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res. 1997 Mar 1;57(5):995-1002.
Results Reference
background
PubMed Identifier
7606709
Citation
Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res. 1995 Jul 15;55(14):2959-62.
Results Reference
background
Learn more about this trial
Familial Prostate Cancer
We'll reach out to this number within 24 hrs